Last update at 2025-07-07T20:00:00Z
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
Breakdown | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 | 2021-07-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 | 2021-07-31 |
Income before tax | -26.47000M | -41.64200M | -41.64200M | -29.19400M | -29.19400M |
Minority interest | - | - | - | - | - |
Net income | -24.94700M | -39.18900M | -39.18900M | -26.31600M | -26.31600M |
Selling general administrative | 2.91M | 2.29M | 2.29M | 8.14M | 8.14M |
Selling and marketing expenses | 16.86M | 11.23M | 11.23M | 8.14M | 8.14M |
Gross profit | 7.57M | 7.24M | 7.24M | 2.02M | 2.02M |
Reconciled depreciation | 3.67M | 3.01M | 3.01M | 2.38M | 2.38M |
Ebit | -26.71700M | -28.88100M | -28.88100M | -29.06600M | -29.06600M |
Ebitda | -23.04600M | -25.86900M | -25.86900M | -26.69000M | -26.69000M |
Depreciation and amortization | 3.67M | 3.01M | 3.01M | 2.38M | 2.38M |
Non operating income net other | - | - | - | - | - |
Operating income | -26.71700M | -32.64500M | -32.64500M | -29.08300M | -29.08300M |
Other operating expenses | 49.96M | 37.47M | 37.47M | 32.02M | 32.02M |
Interest expense | 14.73M | 2.70M | 2.70M | 0.13M | 0.13M |
Tax provision | -2.37000M | -2.10200M | -2.10200M | -2.82000M | -2.82000M |
Interest income | 0.66M | 0.09M | 0.09M | 0.02M | 0.02M |
Net interest income | -14.64300M | -2.61000M | -2.61000M | -0.11100M | -0.11100M |
Extraordinary items | - | - | - | - | - |
Non recurring | - | - | - | - | - |
Other items | - | - | - | - | - |
Income tax expense | -2.37000M | -2.10200M | -2.10200M | -2.82000M | -2.82000M |
Total revenue | 23.25M | 9.65M | 9.65M | 2.94M | 2.94M |
Total operating expenses | 34.29M | 35.06M | 35.06M | 31.10M | 31.10M |
Cost of revenue | 15.67M | 2.41M | 2.41M | 0.92M | 0.92M |
Total other income expense net | 0.25M | -8.99700M | -8.99700M | -0.11100M | -0.11100M |
Discontinued operations | - | - | - | 0.06M | 0.06M |
Net income from continuing ops | -24.94700M | -39.54000M | -39.54000M | -26.37400M | -26.37400M |
Net income applicable to common shares | - | - | - | -26.31600M | -26.31600M |
Preferred stock and other adjustments | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 | 2021-07-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 | 2021-07-31 |
Total assets | 73.19M | 92.65M | 92.65M | 47.00M | 47.00M |
Intangible assets | 13.80M | 12.09M | 12.09M | 6.39M | 6.39M |
Earning assets | - | - | - | - | - |
Other current assets | 2.24M | 1.76M | - | 3.75M | 1.28M |
Total liab | 51.39M | 74.21M | 74.21M | 5.78M | 5.78M |
Total stockholder equity | 21.80M | 18.44M | 18.44M | 41.22M | 41.22M |
Deferred long term liab | - | - | - | 6.05M | 6.05M |
Other current liab | 7.92M | -8.43100M | 39.10M | -3.64600M | 0.35M |
Common stock | 28.50M | 26.68M | 26.68M | 25.47M | 25.47M |
Capital stock | 28.42M | 26.68M | 26.68M | 25.39M | 25.39M |
Retained earnings | -85.75300M | -65.99700M | -65.99700M | -34.09300M | -34.09300M |
Other liab | - | - | - | - | - |
Good will | 17.04M | 14.23M | 14.23M | 1.54M | 1.54M |
Other assets | - | - | - | 6.05M | 6.05M |
Cash | 16.63M | 41.78M | 41.78M | 26.19M | 26.19M |
Cash and equivalents | - | - | - | - | - |
Total current liabilities | 45.11M | 67.61M | 67.61M | 4.37M | 4.37M |
Current deferred revenue | 0.30M | 38.23M | 38.23M | 0.05M | - |
Net debt | 6.50M | -17.93800M | -17.93800M | -24.48800M | -24.48800M |
Short term debt | 17.39M | 20.09M | 20.09M | 0.29M | 0.29M |
Short long term debt | 16.26M | 18.73M | 18.73M | 0.00000M | - |
Short long term debt total | 23.13M | 23.84M | 23.84M | 1.70M | 1.70M |
Other stockholder equity | 79.01M | 57.75M | 57.75M | 49.84M | 49.84M |
Property plant equipment | - | - | - | 4.34M | 4.34M |
Total current assets | 28.04M | 55.55M | 55.55M | 34.74M | 34.74M |
Long term investments | - | - | - | - | - |
Net tangible assets | - | - | - | 39.34M | 39.34M |
Short term investments | - | - | - | - | - |
Net receivables | 8.82M | 10.33M | 5.58M | 4.61M | 4.61M |
Long term debt | 0.22M | 0.00000M | - | - | - |
Inventory | 2.58M | 1.68M | 1.68M | 0.19M | 0.19M |
Accounts payable | 9.22M | 8.42M | 8.42M | 3.73M | 3.73M |
Total permanent equity | - | - | - | - | - |
Noncontrolling interest in consolidated entity | - | - | - | - | - |
Temporary equity redeemable noncontrolling interests | - | - | - | - | - |
Accumulated other comprehensive income | 0.05M | -1.67900M | - | -1.72500M | - |
Additional paid in capital | - | - | - | - | - |
Common stock total equity | - | - | - | - | - |
Preferred stock total equity | - | - | - | - | - |
Retained earnings total equity | - | - | - | - | - |
Treasury stock | - | - | - | - | - |
Accumulated amortization | - | - | - | - | - |
Non currrent assets other | 0.00000M | 2.98M | 2.98M | - | - |
Deferred long term asset charges | - | - | - | - | - |
Non current assets total | 45.16M | 37.10M | 37.10M | 12.27M | 12.27M |
Capital lease obligations | 7.03M | 5.11M | 5.11M | 1.70M | 1.70M |
Long term debt total | - | - | - | - | - |
Breakdown | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 | 2021-07-31 |
---|---|---|---|---|---|
Type | yearly | yearly | yearly | yearly | yearly |
Date | 2023-12-31 | 2022-12-31 | 2022-07-31 | 2021-12-31 | 2021-07-31 |
Investments | -9.00100M | -25.04200M | -25.04200M | 20.02M | 20.02M |
Change to liabilities | - | 0.00000M | 0.00000M | 0.46M | 0.46M |
Total cashflows from investing activities | - | - | - | 18.70M | 18.70M |
Net borrowings | - | - | - | -0.29000M | -0.29000M |
Total cash from financing activities | -1.29800M | 56.90M | 56.90M | 0.23M | 0.23M |
Change to operating activities | - | - | - | - | - |
Net income | -24.94700M | -39.18900M | -39.18900M | -26.31600M | -26.31600M |
Change in cash | -25.15400M | 15.59M | 15.59M | -1.70300M | -1.70300M |
Begin period cash flow | 41.78M | 26.19M | 26.19M | 27.89M | 27.89M |
End period cash flow | 16.63M | 41.78M | 41.78M | 26.19M | 26.19M |
Total cash from operating activities | -14.87200M | -16.43200M | -16.43200M | -20.50600M | -20.50600M |
Issuance of capital stock | 0.40M | 9.49M | 9.49M | 0.52M | 0.52M |
Depreciation | 3.67M | 3.01M | 3.01M | 2.38M | 2.38M |
Other cashflows from investing activities | - | - | - | - | - |
Dividends paid | - | - | - | - | - |
Change to inventory | 0.20M | 0.05M | 0.05M | 0.01M | 0.01M |
Change to account receivables | 0.84M | 2.23M | - | -1.59900M | -1.59900M |
Sale purchase of stock | - | - | - | - | - |
Other cashflows from financing activities | -0.24600M | 47.42M | 47.42M | -0.29000M | -0.29000M |
Change to netincome | - | 15.88M | 15.88M | 4.61M | 4.61M |
Capital expenditures | 1.26M | 0.76M | 0.76M | 1.31M | 1.31M |
Change receivables | - | - | - | - | - |
Cash flows other operating | - | - | - | - | - |
Exchange rate changes | - | - | - | - | - |
Cash and cash equivalents changes | - | - | - | - | - |
Change in working capital | 0.74M | 3.87M | 3.87M | -1.13000M | -1.13000M |
Stock based compensation | 2.91M | 7.49M | 7.49M | 5.08M | 5.08M |
Other non cash items | 12.25M | 8.66M | 8.38M | 0.12M | -0.51900M |
Free cash flow | -16.13400M | -17.19100M | -17.19100M | -21.82000M | -21.82000M |
Sector: Healthcare Industry: Biotechnology
Company | Change (USD) | Price (USD) | Trailing PE (x) | Forward PE (x) | Price Sales TTM (x) | Price to Book Value (x) | Enterprise Value to Revenue (x) | Enterprise Value to EBITDA (x) |
---|---|---|---|---|---|---|---|---|
AVCTF Avacta Group Plc |
- -% | 0.40 | - | - | 9.57 | 3.35 | 7.00 | -14.8007 |
NVO Novo Nordisk A/S |
-0.5201 0.75% | 68.80 | 41.58 | 31.15 | 2.13 | 32.99 | 2.11 | 4.70 |
NONOF Novo Nordisk A/S |
- -% | 70.12 | 41.06 | 31.25 | 2.08 | 33.11 | 2.11 | 4.70 |
VRTX Vertex Pharmaceuticals Inc |
10.38 2.26% | 469.79 | 29.67 | 24.33 | 10.38 | 5.83 | 9.33 | 20.00 |
REGN Regeneron Pharmaceuticals Inc |
18.29 3.40% | 556.40 | 29.07 | 20.12 | 7.57 | 3.82 | 6.95 | 19.42 |
Avacta Group Plc develops cancer drugs and in vitro diagnostics in the United Kingdom, France, North America, South Korea, rest of Europe, and internationally. The company operates through Diagnostics and Therapeutics segments. It provides its proprietary Affimer and pre|CISION technology platforms, which is used to deliver a portfolio of differentiated th therapeutic and diagnostic products that addresses various markets. The company develops AVA6000, a peptide drug conjugate form of doxorubicin that is in Phase I clinical trial to treat locally advanced or metastatic solid tumour; AVA3996, a tumor-activated proteasome inhibitor based on Velcade; and AVA032, a bispecific molecule which is in pre-clinical trials that regulates the activation and proliferation of immune cells. It develops AVA-028-PD-L1 Affimer/ImmunoCytokines; AVA-021 - PD-L1 Affimer/LAG-3 Affimer; and TMAC platform that utilizes the proprietary pre|CISION substrate to provide for the selective release of a drug moiety by FAPa. The company has a collaboration agreement with LG Chem for developing and commercializing Affimer based therapeutics. Avacta Group Plc was incorporated in 2003 and is based in Wetherby, the United Kingdom.
Thorp Arch Estate, Wetherby, United Kingdom, LS23 7FA
Name | Title | Year Born |
---|---|---|
Dr. David Alastair Smith | CEO & Exec. Director | NA |
Mr. Tony Gardiner | CFO, Company Sec. & Exec. Director | 1971 |
Ms. Emma Wright | Group In-House Counsel | NA |
Mr. Michael Vinegrad | Group Communications Director | NA |
Dr. Matt Johnson | Chief Scientific Officer of Diagnostics | NA |
Dr. Neil Bell | Chief Devel. Officer of Therapeutics | 1958 |
Dr. Fiona McLaughlin FSB, Ph.D. | Chief Scientific Officer of Therapeutics Division | 1970 |
Mr. Marc Green | Head of Product Devel. - Diagnostics | NA |
Gemma Wilson | Head of QA/RA - Diagnostics | NA |
Mr. Petros Sarantos | Head of Product Management - Diagnostics | NA |
Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.